CTLA4 and metastatic melanoma: High levels of butyrate and propionate are further associated with resistance to CTLA4 blockade in metastatic melanoma patients, and butyrate supplementation reduced anti-CTLA4-induced DC maturation and CD8+ T cell priming in a syngeneic tumor mouse model [148].